Search Results 2101-2110 of 19666 for hemoglobin

1. A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors - Mayo Clinic

   Hemoglobin ≥9.0 g/dL 9. Adequate coagulation parameters based on the following: a. Prothrombin Time-International Normalized Ratio/partial thromboplastin ...

2. Lupus - Diagnosis & treatment - Mayo Clinic

   Laboratory tests · Complete blood count. This test measures the number of red blood cells, white blood cells and platelets, as well as the amount of hemoglobin, ...

3. Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung - Mayo Clinic

   - Hemoglobin >= 9.0 g/dl (obtained within 14 days prior to registration. For participants who received a cycle of chemotherapy prior to registration, at ...

4. A Study to Evaluate Safety of Enapotamab Vedotin in Patients with Solid Tumors - Mayo Clinic

   Hemoglobin ≥ 5.6 mmol/L (~ 9 g/dL);; Absolute neutrophil count (ANC) ≥ 1500/μL (1.5 x 10^9/L);; Platelet count ≥ 100 x10^9/L. Have an Eastern Cooperative ...

5. A Study to Evaluate the Effectiveness of Intravenous Iron Sucrose in Patients with Non-anemic Iron Deficiency and Postural Orthostatic Tachycardia Syndrome (POTS) - Mayo Clinic

   Presence of non-anemic iron deficiency, defined as serum ferritin levels < 20 ug/L with hemoglobin no less than 1 gm/dL below the normal reference range as ...

6. A Study to Test Combination Treatments in Patients With Advanced Gastric Cancer - Mayo Clinic

   Hemoglobin ≥ 9.0 g/dL (transfusion to achieve this level is not permitted within 2 weeks of the first study treatment administration);; Alanine ...

7. A Study to Evaluate Effectiveness and Safety of Ustekinumab Re-induction Therapy in Participants With Moderate to Severely Active Crohn's Disease (POWER) - Mayo Clinic

   Hemoglobin ≥ 8.5 g/dL (≥ 85 g/L);; White blood cell (WBC) count ≥ 3.5 x 10^3 /µL (≥ 3.5 GI/L);; Neutrophils ≥ 1.5 x 10^3 /µL (≥ 1.5 GI/L);; Platelets ...

8. A Study to Evaluate DS-8201a Combined with Olaparib in HER2-Expressing Cancers with Expansion in Endometrial Cancer Patients Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Endometrial Cancer - Mayo Clinic

   Hemoglobin ≥ 10.0 g/dL;; Absolute neutrophil count ≥ 1,000/mcL**;; Platelets ≥ 100,000/mcL*;; Total bilirubin ≤ 1.5 × institutional upper limit of normal ...

9. Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis (NAVIGATE) - Mayo Clinic

   ... hemoglobin [HbA1c] ≥ 6.5%, or on anti-diabetic medication for at least 1 year); or dyslipidemia (triglycerides ≥150 mg/dL or on drug therapy for ...

10. Medical Research & Education - Mayo Clinic News Network

    Science Saturday: Research Roundup featured image · Research · New oral anticoagulant drugs associated with lower kidney risks, Mayo Clinic research shows ...